Pulmonary Hypertension Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Newborn babies who received at least one dose of a medication called treprostinil (given by injection into a vein or under the skin) as part of their normal medical care within the past 5 years.
- Babies who were no more than 44 weeks from the time of conception when they first started receiving treprostinil (this includes premature babies counted from their due date).
- Babies who had, or were suspected of having, high blood pressure in the lungs (a condition called pulmonary hypertension) when they first started receiving treprostinil.
- Babies whose parent(s) or legal guardian(s) have agreed to allow their child's information to be used in the study.
- Babies who are registered with the French social security system.
Who may not be able to join:
- No specific exclusion criteria have been listed for this trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 609850565
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Characteristics of neonates receiving treprostinil in the clinical practice.; Treprostinil-specific treatment patterns.; Number of participants with treatment-related adverse events to evaluate safety.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.